Journal of geriatric oncology最新文献

{"title":"Adding comprehensive geriatric assessment to standard of care in older patients with frailty and hematological cancer: A pilot and feasibility study","authors":"Nina Andersen , Ann Kristine Weber Giger , Dana Audrey Lawrie , Wee Kheng Soo , Cecilia Margareta Lund , Jesper Ryg , Henrik Frederiksen","doi":"10.1016/j.jgo.2025.102835","DOIUrl":"10.1016/j.jgo.2025.102835","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102835"},"PeriodicalIF":2.7,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145733164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to modernise research in geriatric oncology: Reflections from the 2025 International Society of Geriatric Oncology Annual Meeting","authors":"Sophie Pilleron","doi":"10.1016/j.jgo.2025.102837","DOIUrl":"10.1016/j.jgo.2025.102837","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102837"},"PeriodicalIF":2.7,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145756943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring decisional control preferences in older patients with cancer and their caregivers","authors":"Sofiia Hryniv ,&nbsp;Elizabeth Gilbride ,&nbsp;William Consagra ,&nbsp;Supriya Mohile ,&nbsp;Sule Yilmaz ,&nbsp;Kaitlin Kyi ,&nbsp;Sindhuja Kadambi ,&nbsp;Marielle Jensen-Battaglia ,&nbsp;Nikesha Gilmore ,&nbsp;Mary Whitehead ,&nbsp;Jamil Khatri ,&nbsp;Fadi S. Braiteh ,&nbsp;Alison Conlin ,&nbsp;Kah Poh Loh ,&nbsp;Allison Magnuson","doi":"10.1016/j.jgo.2025.102832","DOIUrl":"10.1016/j.jgo.2025.102832","url":null,"abstract":"<div><h3>Introduction</h3><div>Exploring informational and decisional control preferences as well as examining concordance and patient-caregiver-physician factors associated with preferences in older adults with cancer and their caregivers may help to better understand the role of caregivers in supporting decision-making.</div></div><div><h3>Materials and methods</h3><div>We utilized data from a national geriatric assessment (GA) cluster-randomized trial (NCT 02054741; PI: Mohile) that recruited patients aged ≥70 with incurable cancer, their caregivers, and oncologists. Dyadic decision-making control preferences were measured by the Control Preferences Scale (CPS). Patients and caregivers were asked to describe patient's role in treatment decision-making (patient-role CPS); patients and caregivers were also asked to describe the caregiver's role in treatment decision-making (caregiver-role CPS). Matching patient-caregiver responses were considered concordant. Patients and caregivers were also asked about their information preferences regarding the amount of detail about the patients' illness using a scale from 1 (fewest detail) to 5 (the most detail). We used descriptive statistics to summarize CPS, informational preferences, and concordance in responses. We utilized logistic regression to assess dyads' sociodemographic information, patients' GA domain impairments, and physicians' practice characteristics associated with patient-caregiver CPS concordance.</div></div><div><h3>Results</h3><div>A total of 332 dyads participated; mean age (SD) of patients and caregivers was 76.6 (5.3) and 66.6 (12.2), respectively. Preferences for treatment decision-making varied, with some preferring shared decision-making and others preferring the doctor to make decisions. Concordance between patients and caregivers was observed in 46 % for patient-role CPS and 54 % for caregiver-role CPS. Baseline factors were not associated with dyad concordance. The majority of patients and caregivers preferred the most detailed information about the patient's illness.</div></div><div><h3>Discussion</h3><div>Clinicians should assess patients' and caregivers' informational and decisional control preferences for optimal support in decision-making.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102832"},"PeriodicalIF":2.7,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145735296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of CDK4/6 inhibitors in older patients: A FAERS-based analysis of serious and fatal adverse events","authors":"Fausto Petrelli ,&nbsp;Alessandro Iaculli ,&nbsp;Maria Chiara Parati ,&nbsp;Karen Borgonovo ,&nbsp;Mara Ghilardi ,&nbsp;Veronica Lonati ,&nbsp;Irene Angeli ,&nbsp;Lorenzo Dottorini","doi":"10.1016/j.jgo.2025.102820","DOIUrl":"10.1016/j.jgo.2025.102820","url":null,"abstract":"<div><h3>Introduction</h3><div>CDK4/6 inhibitors—abemaciclib, palbociclib, and ribociclib—are standard treatments for hormone receptor–positive, ERBB2 (HER2)-negative metastatic breast cancer. However, older adults are underrepresented in clinical trials, and age-related safety data remain limited in real-world settings.</div></div><div><h3>Materials and Methods</h3><div>We conducted a pharmacovigilance analysis using 44,100 individual case safety reports (ICSRs) from the FDA Adverse Event Reporting System (FAERS) involving patients aged ≥65 years treated with CDK4/6 inhibitors. Primary endpoints included serious adverse events (SAEs) and fatal outcomes. A secondary analysis compared adverse events between patients aged &lt;65 and 65–85 years, calculating odds ratios (ORs) for selected toxicities, including death, disease progression, diarrhea, and myelosuppression.</div></div><div><h3>Results</h3><div>Among older patients, 71.2 % of reports involved SAEs and 5.3 % were fatal. Abemaciclib was linked to higher risk of death in those aged 65–85 compared to younger adults (OR 1.53; 95 % CI 1.18–1.99), but lower odds of myelosuppression (OR 0.37; 95 % CI 0.26–0.53). Palbociclib showed similar death risk across age groups (OR 0.98; 95 % CI 0.92–1.05) and reduced risk of disease progression in older adults (OR 0.72; 95 % CI 0.61–0.84). Ribociclib showed no significant age-related difference in fatality (OR 1.01; 95 % CI 0.87–1.17) but had the highest overall death risk (OR 9.14 vs palbociclib; 95 % CI 7.70–10.84).</div></div><div><h3>Discussion</h3><div>Real-world data reveal drug- and age-specific toxicity differences. Ribociclib and abemaciclib pose higher risks in older adults compared to palbociclib, supporting the need for personalized treatment and careful monitoring in older patients.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102820"},"PeriodicalIF":2.7,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145735292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do we need geriatricians in geriatric oncology? A SIOG geriatricians position statement","authors":"Carolina Gómez-Moreno ,&nbsp;Chiara Russo ,&nbsp;Armida Parala-Metz ,&nbsp;Bérengère Beauplet ,&nbsp;Anupa Pillai ,&nbsp;Anand Kumar ,&nbsp;Domenico Fusco ,&nbsp;Suzanne Festen ,&nbsp;Siri Rostoft","doi":"10.1016/j.jgo.2025.102831","DOIUrl":"10.1016/j.jgo.2025.102831","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102831"},"PeriodicalIF":2.7,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145735291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BDNF genotype and cognition in older adults with breast cancer and healthy controls in the Thinking and Living with Cancer Study","authors":"Zev M. Nakamura ,&nbsp;Brent J. Small ,&nbsp;Xingtao Zhou ,&nbsp;Jaeil Ahn ,&nbsp;Tim A. Ahles ,&nbsp;Ashley L. Artese ,&nbsp;Harvey Jay Cohen ,&nbsp;Martine Extermann ,&nbsp;Deena Graham ,&nbsp;Claudine Isaacs ,&nbsp;Heather S.L. Jim ,&nbsp;Brenna C. McDonald ,&nbsp;Kelly Nudelman ,&nbsp;Sunita K. Patel ,&nbsp;Kelly E. Rentscher ,&nbsp;James C. Root ,&nbsp;Andrew J. Saykin ,&nbsp;Kathleen Van Dyk ,&nbsp;Claire E. Wegel ,&nbsp;Jeanne S. Mandelblatt ,&nbsp;Judith E. Carroll","doi":"10.1016/j.jgo.2025.102834","DOIUrl":"10.1016/j.jgo.2025.102834","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102834"},"PeriodicalIF":2.7,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145735297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reflections on treatment decision making in older adults with cancer","authors":"Vincent E.S. Allott ,&nbsp;Michael B. Fertleman ,&nbsp;Louis J. Koizia ,&nbsp;Benjamin H.L. Harris","doi":"10.1016/j.jgo.2025.102830","DOIUrl":"10.1016/j.jgo.2025.102830","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102830"},"PeriodicalIF":2.7,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145714552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dizziness and impaired postural balance in older patients receiving chemotherapy treatment: A systematic review and meta-analysis","authors":"Katrine Storm Piper ,&nbsp;Martine Puts ,&nbsp;Cecilia Lund ,&nbsp;Jesper Ryg ,&nbsp;Charlotte Suetta ,&nbsp;Hanne Elkjær Andersen ,&nbsp;Jakob Vasehus Schou ,&nbsp;Allan Madsen ,&nbsp;Jan Christensen","doi":"10.1016/j.jgo.2025.102816","DOIUrl":"10.1016/j.jgo.2025.102816","url":null,"abstract":"<div><h3>Introduction</h3><div>Dizziness and balance impairments are underexplored symptoms in older adults with cancer. Age-related factors, comorbidities, and chemotherapy may contribute to its prevalence and severity, potentially affecting quality of life, increasing fall risk, and delaying treatment. Data on the incidence and prevalence of these symptoms are limited. This systematic review aimed to summarize the evidence and estimate the incidence and prevalence of dizziness or vertigo and impaired postural balance in patients with cancer ≥65 years receiving chemotherapy.</div></div><div><h3>Materials and Methods</h3><div>We searched PubMed, EMBASE, CENTRAL, and CINAHL in May 2025 without date or language restrictions. Cross sectional studies, cohort studies, randomized controlled trials, and mixed method studies investigating incidence and/or prevalence of dizziness or vertigo and impaired postural balance were included. Random-effects meta-analysis, employing the inverse-variance method, was applied. Certainty of evidence was rated by the Grading of Recommendations Assessment and Evaluation (GRADE) approach.</div></div><div><h3>Results</h3><div>From 15,614 title/abstracts screened, 14 studies (1259 participants) were included. Incidence could not be evaluated. Studies reporting prevalence across multiple chemotherapy regimens contributed separate estimates for each regimen. Meta-analysis included 25 prevalence estimates for dizziness and three for impaired postural balance. The pooled prevalence of dizziness was 15 % (95 % CI:10 %–22 %). Assessor-reported prevalence using the Common Terminology Criteria for Adverse Events (CTCAE) was 11 % (95 % CI: 8 %–16 %), while patient-reported prevalence rate using the European Organisation for Research and Treatment of Cancer Chemotherapy Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20), or a self-constructed questionnaire was 35 % (95 % CI: 20 %–53 %). Most studies demonstrated a high risk of bias, and certainty of evidence was very low due to unstructured assessor-reported measurement methods. Impaired postural balance prevalence from one study was 48 % (95 % CI: 39 %–57 %) with low certainty of evidence. Prevalence of dizziness and impaired postural balance did not differ significantly across chemotherapy regimens.</div></div><div><h3>Discussion</h3><div>Prevalence of dizziness and impaired postural balance in older patients receiving chemotherapy varied substantially depending on the measurement method, with higher rates in patient-reported outcomes. Certainty of evidence was low primarily due to limitations in outcome measures. Future studies should incorporate patient-reported outcome measures and a systematic objective baseline assessment for a comprehensive evaluation of these symptoms.</div><div>Trial registration: PROSPERO CRD42024585974.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102816"},"PeriodicalIF":2.7,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145692902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a new model for prediction of relevant treatment related adverse events in older individuals with gastrointestinal cancers","authors":"Vallish Shenoy ,&nbsp;Sadhana Kannan ,&nbsp;Vanita Noronha ,&nbsp;Kumar Prabhash ,&nbsp;Vikas Ostwal ,&nbsp;Prabhat Bhargava ,&nbsp;Anupa Pillai ,&nbsp;K. Shamseeya ,&nbsp;Ankush Shetake ,&nbsp;Ratan Dhekale ,&nbsp;Ankita Chitre ,&nbsp;Vikram Gota ,&nbsp;Sarika Mahajan ,&nbsp;Anuradha Daptardar ,&nbsp;Lekhika Sonkusare ,&nbsp;Jayita Deodhar ,&nbsp;Nabila Ansari ,&nbsp;Manjusha Vagal ,&nbsp;Purabi Mahajan ,&nbsp;Manjunath Nookala ,&nbsp;Anant Ramaswamy","doi":"10.1016/j.jgo.2025.102817","DOIUrl":"10.1016/j.jgo.2025.102817","url":null,"abstract":"<div><h3>Introduction</h3><div>Limited tools exist to specifically predict the risk of chemotherapy toxicity and related events in older individuals with gastrointestinal (GI) cancers.</div></div><div><h3>Materials and Methods</h3><div>We evaluated patients aged ≥60 years with GI cancers who underwent a comprehensive geriatric assessment comprising demographic, cancer variables, and geriatric domains (function, comorbidities, nutritional status, medications, cognition, psychological status, and social support). A Cancer and Aging Research Group (CARG) score was calculated in all patients. The occurrence of grade 3 to 5 adverse events, emergent hospitalizations, and sudden death without identifiable adverse events were defined as treatment related adverse events (TRAE) to form the new predictive model. Based on initial univariate analysis of factors predicting for TRAE and then multivariate analysis, a nomogram was developed to predict the probability TRAEs. The total score derived from the nomogram was categorized into low, moderate, and high-risk groups based on a recursive partitioning algorithm.</div></div><div><h3>Results</h3><div>In total, 701 patients with a median age of 67 years (range, 60 to 88 years) with predominantly stage IV cancers (58 %) were analysed. The distribution of GI cancers was gastric and esophageal cancers (<em>n</em> = 349, 50 %), hepatobiliary and pancreatic cancers (<em>n</em> = 241, 34 %), and colorectal cancers (<em>n</em> = 84, 12 %). TRAE occurred in 53 % of the patients. A predictive model for TRAE was developed using the Mobility-Tiredness (Mob-T) Scale, hearing, cancer stage, site of primary, and chemotherapy dosing (standard or reduced). A predictive score in which the median risk score was 22 (range, 0 to 40) and risk stratification identified older adults at low risk (0 to 13 points; 17 %), intermediate risk (14 to 21 points; 40 %), or high risk (&gt;22 points; 71 %) of chemotherapy toxicity (<em>P</em> &lt; 0.001). The new model outperformed the CARG score based on ROC analysis (0.75 vs 0.59, <em>p</em> &lt; 0.001).</div></div><div><h3>Discussion</h3><div>A new and simpler risk score predicts for chemotherapy related adverse events in older patients with GI cancers and seems to be more accurate than the CARG score. The score requires validation in prospective studies.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102817"},"PeriodicalIF":2.7,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145692903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of a 12-week multicomponent exercise programme on physical function in older adults with cancer: Study protocol for the ONKO-FRAIL randomised controlled trial","authors":"Julia García-García ,&nbsp;Ana Rodriguez-Larrad ,&nbsp;Maren Martinez de Rituerto Zeberio ,&nbsp;Jenifer Gómez Mediavilla ,&nbsp;Borja López-San Vicente ,&nbsp;Nuria Torrego Artola ,&nbsp;Izaskun Zeberio Etxetxipia ,&nbsp;Irati Garmendia ,&nbsp;Ainhoa Alberro ,&nbsp;David Otaegui ,&nbsp;Francisco Borrego Rabasco ,&nbsp;María M. Caffarel ,&nbsp;Kalliopi Vrotsou ,&nbsp;Jon Irazusta ,&nbsp;Haritz Arrieta ,&nbsp;Mireia Pelaez ,&nbsp;Jon Belloso ,&nbsp;Laura Basterretxea","doi":"10.1016/j.jgo.2025.102818","DOIUrl":"10.1016/j.jgo.2025.102818","url":null,"abstract":"<div><h3>Introduction</h3><div>Cancer in older adults is often associated with functional limitations, geriatric syndromes, poor self-rated health, vulnerability, and frailty, and these conditions might worsen treatment-related side effects. Recent guidelines for patients with cancer during and after treatment have documented the beneficial effects of exercise to counteract certain side effects; however, little is known about the role of exercise during cancer treatment in older adults.</div></div><div><h3>Materials and Methods</h3><div>This is a multicentre randomised controlled trial in which 200 participants will be allocated to a control group or an intervention group (the sample size has been calculated to detect a clinical difference of 1 point in Short Physical Performance Battery (SPPB) score, assuming an α error of 0.05, a β error of 0.20, and a 10 % loss rate). Patients aged ≥70 years, diagnosed with any type of solid cancer and candidates for systemic treatment are eligible. Subjects in the intervention group are invited to participate in a 12-week supervised multicomponent exercise programme in addition to receiving usual care. Study assessments are conducted at baseline and three months. The primary outcome measure is physical function as assessed by the SPPB. Secondary outcome measures include comprehensive geriatric assessment scores (including social situation, basic and instrumental activities of daily living, cognitive function, depression, nutritional status, polypharmacy, geriatric syndromes, pain, and emotional distress), anthropometric characteristics, frailty status, physical fitness, physical activity, cognitive function, quality of life, fatigue, and nutritional status. Study assessments also include analysis of inflammatory, endocrine, and nutritional mediators in serum and plasma as potential frailty biomarkers at mRNA and protein levels and multiparametric flow cytometric analysis to measure immunosenescence markers on T and NK cells.</div></div><div><h3>Discussion</h3><div>This study seeks to extend our knowledge on exercise interventions during systemic anticancer treatment in patients over 70 years of age. Results from this research will guide the management of older adults during systemic treatment in hospitals seeking to enhance the standard of care.</div></div><div><h3>Trial registration</h3><div><span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> Identifier: <span><span>NCT05131113</span><svg><path></path></svg></span>, November 11, 2021.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102818"},"PeriodicalIF":2.7,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145665429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}